Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease
Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease
复制标题
肠道菌群：炎症性肠病治疗方法的新目标
DOI：
10.1517/14728222.12.3.301
复制
发表时间：
2008
影响因子：
5.8
通讯作者：
M. Sata
中科院分区：
文献类型：
--
作者：
K. Mitsuyama;M. Sata
背景：肠道菌群参与炎症性肠病的发病机制，包括溃疡性结肠炎和克罗恩病。目的：这篇综述总结了目前临床知识的作用，肠道菌群在炎症性肠病和他们的重要性，为新形式的治疗目标。研究方法：总结了与炎症性肠病相关的肠道微生物生态学、微生物区系的作用和模式识别受体的最新知识。简要介绍了益生元、益生菌和合生元等靶向微生物菌群制剂的体外实验、体内动物研究和人体临床试验结果。结论：通过益生元、益生菌和合生元改变肠道菌群的组成可能会改善炎症性肠病患者的临床结局。
Background: Intestinal microflora contribute to the pathogenesis of inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Objective: This review summarizes current clinical knowledge about the role of intestinal microflora in inflammatory bowel disease and their importance as targets for new forms of therapy. Methods: Recent knowledge on gut microbial ecology, role of microflora, and pattern recognition receptors is summarized in relation to inflammatory bowel disease. The results of in vitro experiments, in vivo animal studies and human clinical trials with the use of agents targeting microflora, including prebiotics, probiotics and synbiotics, are described briefly. Conclusion: Altering the composition of intestinal microflora through prebiotics, probiotics and synbiotics may improve the clinical outcome of patients with inflammatory bowel disease.
影响因子：
15.9
作者：
Strober, Warren;Fuss, Ivan;Mannon, Peter
通讯作者：
Mannon, Peter
影响因子：
29.4
作者：
Hisamatsu, T;Suzuki, M;Podolsky, DK
通讯作者：
Podolsky, DK
DOI：
10.1152/ajpgi.00544.2005
发表时间：
2006-06-01
影响因子：
4.5
作者：
Gewirtz, AT;Vijay-Kumar, M;Cho, JH
通讯作者：
Cho, JH